Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Insulet Corp Lowers High End Of Prior FY 2012 Revenue Guidance In Line With Estimates; Raises Low End Of Prior FY 2012 EBIT Guidance Below Estimates; Issues Q4 2012 Revenue Guidance
Insulet Corp announced that for fiscal 2012, it expects revenue to be in the range of $210-$215 million and its estimate for operating loss to be in the range of $35-$38 million. For fourth quarter of 2012, it expects revenue of $56.5-$61.5 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $214 million and EBIT of $(33) million for fiscal 2012; revenue of $60.1 million for fourth quarter of 2012.
Latest Developments for Insulet Corp
- Insulet Corp Reiterates FY 2013 Revenue Guidance; Issues Q2 2013 Revenue Guidance In Line With Analysts' Estimates
- Insulet Corp Issues Q1, FY 2013 Revenue Guidance Below Analysts' Estimates
- Insulet Corp Receives FDA Clearance For Omnipod Insulin Management System
- Insulet Corporation Issues Q3 2012 Revenue Guidance; Lowers High End Of Prior FY 2012 Revenue Guidance In Line With Analysts' Estimates; Lowers FY 2012 Operating Income
- Share this
- Link this
- Digg this
Follow Reuters